Akshat Jain Explores a New Blood Journals Study on the Bleeding Burden in Type 1 VWD
Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared on LinkedIn:
”Novel Bispecific Nanobody
New study out in Blood Journals Portfolio on addressing the bleeding burden in Type 1 VWD patients and development of novel therapy options for these patients via SubCutanous route!
American Society of Hematology
KB-V13A12 is designed to increase the patient’s own von Willebrand factor (VWF) levels by bridging VWF to albumin, potentially enhancing VWF survival in the bloodstream.
KB-V13A12 is a bispecific nanobody that binds both VWF and albumin, aiming to harness the recycling pathway of albumin to protect and maintain higher circulating VWF levels.
In laboratory experiments, the nanobody efficiently tethered VWF to albumin without interfering with VWF’s ability to bind Factor VIII or function in clot formation.
In VWD type 1 mouse models, a single subcutaneous dose of KB-V13A12 led to a rapid, dose-dependent increase in VWF levels—up to 2.1-fold—for up to two weeks.
This elevation translated to significantly improved bleeding control in treated mice, using established bleeding models.”
Read the full article in Blood.
Article: A bispecific nanobody for the treatment of von Willebrand disease type 1
Authors: Ivan Peyron, Caterina Casari, Geneviève McCluskey, Vincent Licari, Emilie Bocquet, Claire Auditeau, Mélanie Y. Daniel, Stéphanie Roullet, Sophie Susen, Olivier D. Christophe, Peter J. Lenting, Cécile V. Denis
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 7, 2026, 08:50Fahad Khaliq on When is Ticagrelor Preferred Over Other Antiplatelets
-
Jan 7, 2026, 06:41Zain Khalpey on AI Driven Risk Prediction for Optimization of Anticoagulation in LVAD
-
Jan 7, 2026, 05:47Michael Makris: The Wakley Prize Essay Published in Today’s Lancet is an Excellent Read
-
Jan 7, 2026, 05:36Pierre F Sabouret Shares A Study on the Risk of Cardiovascular Death in SIDs
-
Jan 7, 2026, 05:15Glaivy Batsuli Reflects on ASH25
-
Jan 7, 2026, 05:04Heghine Khachatryan on VWD: A Landmark in the History of Hematology
-
Jan 6, 2026, 13:39JAMA Neurology: No Added Benefit of Dual Therapy After Ischemic Stroke in Case of AFib
-
Jan 6, 2026, 10:10This is Fantastic: Shirley D’Sa on Transfusion-Free Christmas Milestone for 𝛃-Thalassaemia Patient at UCLH
-
Jan 6, 2026, 09:53Hamideh Yadegari: Coagulation–Inflammation Crosstalk: Mechanisms, Pathways, and Clinical Implications